Shots:

• The approval is based on the 2 (KEEPsAKE-1 /2) studies evaluating Skyrizi (150mg, SC) vs PBO in adults with active PsA who had responded inadequately or were intolerant to biologic therapy & non-biologic DMARDs
• The trial met the 1EPs i.e., @24wks., patients achieved the ACR20 response (57.3% & 51.3% vs 33.5% & 26.5%), improvements in ACR50, ACR70 responses, physical function, joint symptoms, improvements in other manifestations of PsA including dactylitis & enthesitis, skin lesions of psoriasis & the safety profile was consistent with patients with PsO
• Skyrizi is an IL-23 inhibitor that blocks IL-23 by binding to its p19 subunit while P-III trials in psoriasis, CD, UC & PsA are ongoing

Ref: AbbVie | Image: abbvie